» Articles » PMID: 37233852

2023 Update on Italian Guidelines for the Treatment of Type 2 Diabetes

Citing Articles

Generalizability of kidney and cardiovascular protection by finerenone to the real world in Italy: insights from Fidelio and Figaro studies.

De Cosmo S, Pontremoli R, Giandalia A, Manicardi V, Rocca A, Nicolucci A J Nephrol. 2024; .

PMID: 39676127 DOI: 10.1007/s40620-024-02171-8.


Glycaemic response to pasta from three different wheat varieties in individuals with type 2 diabetes.

Dicembrini I, Cavallo G, Ranaldi F, Scoccimarro D, Caiulo C, Silverii G Diabetes Obes Metab. 2024; 27(2):1014-1017.

PMID: 39587365 PMC: 11701172. DOI: 10.1111/dom.16082.


Systematic review of guideline recommendations for older and frail adults with type 2 diabetes mellitus.

Bolt J, Carvalho V, Lin K, Lee S, Inglis C Age Ageing. 2024; 53(11).

PMID: 39572394 PMC: 11581819. DOI: 10.1093/ageing/afae259.


Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study.

Khare S, Osumili B, Debackere N, Keapoletswe K, Falato S, Raoul T Adv Ther. 2024; 42(1):174-192.

PMID: 39487881 PMC: 11782337. DOI: 10.1007/s12325-024-03002-9.


Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management.

Grottoli S, Maffei P, Tresoldi A, Granato S, Benedan L, Mariani P J Endocrinol Invest. 2024; 47(12):2999-3017.

PMID: 38809458 PMC: 11549125. DOI: 10.1007/s40618-024-02386-3.


References
1.
Ghardashi-Afousi A, Davoodi M, Hesamabadi B, Asvadi-Fard M, Bigi M, Izadi M . Improved carotid intima-media thickness-induced high-intensity interval training associated with decreased serum levels of Dkk-1 and sclerostin in type 2 diabetes. J Diabetes Complications. 2019; 34(1):107469. DOI: 10.1016/j.jdiacomp.2019.107469. View

2.
Navaneethan S, Zoungas S, Caramori M, Chan J, Heerspink H, Hurst C . Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. Ann Intern Med. 2020; 174(3):385-394. DOI: 10.7326/M20-5938. View

3.
Mannucci E, Gallo M, Giaccari A, Candido R, Pintaudi B, Targher G . Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events. Diabetes Obes Metab. 2022; 25(2):444-453. DOI: 10.1111/dom.14888. View

4.
Jabbour S, Frias J, Ahmed A, Hardy E, Choi J, Sjostrom C . Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Diabetes Care. 2020; 43(10):2528-2536. PMC: 7510043. DOI: 10.2337/dc19-1350. View

5.
Dicembrini I, Mannucci E, Monami M, Pala L . Impact of technology on glycaemic control in type 2 diabetes: A meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion. Diabetes Obes Metab. 2019; 21(12):2619-2625. DOI: 10.1111/dom.13845. View